Selected article for: "high frequency and present study"
Author: Bichara, Carlos David Araújo; da Silva Graça Amoras, Ednelza; Vaz, Gergiane Lopes; da Silva Torres, Maria Karoliny; Queiroz, Maria Alice Freitas; do Amaral, Isabella Pinheiro Costa; Vallinoto, Izaura Maria Vieira Cayres; Bichara, Cléa Nazaré Carneiro; Vallinoto, Antonio Carlos Rosário
Title: Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
  • Cord-id: y2swenh5
  • Document date: 2021_5_15
    • ID: y2swenh5
    Snippet: BACKGROUND: In this study, the prevalence and persistence of anti-SARS-CoV-2 (severe acute respiratory syndrome-coronavirus) IgG was evaluated in volunteers 90 days after COVID-19 (coronavirus disease 2019) diagnosis by correlating response dynamics with clinical conditions, epidemiological characteristics, and disease severity. METHODS: The study recruited 200 volunteers aged 18 years or older of both sexes diagnosed with COVID-19. Of the 200 volunteers initially selected, the 135 individuals w
    Document: BACKGROUND: In this study, the prevalence and persistence of anti-SARS-CoV-2 (severe acute respiratory syndrome-coronavirus) IgG was evaluated in volunteers 90 days after COVID-19 (coronavirus disease 2019) diagnosis by correlating response dynamics with clinical conditions, epidemiological characteristics, and disease severity. METHODS: The study recruited 200 volunteers aged 18 years or older of both sexes diagnosed with COVID-19. Of the 200 volunteers initially selected, the 135 individuals who underwent serological testing for anti-SARS-CoV-2 antibodies on the first visit to the laboratory, were invited to return, after 90 days, and provide a new blood sample for a second assessment of the presence of anti-SARS-CoV-2 IgG antibody. Disease severity and longevity of symptoms were evaluated for each individual and associated with the serological profile. RESULTS: Among the 135 individuals who underwent a previous serological test for anti-SARS-CoV-2 antibody, 125 showed reactivity to IgG (92.6%). Of the 125 individuals with detectable IgG in the first test, 87 (69.6%) showed persistence of this antibody after 90 days and 38 (30.4%) lost IgG reactivity in the second evaluation. The frequency of all reported symptoms was higher in individuals who maintained IgG persistence after 90 days of symptoms. Symptom manifestations lasted ≥21 days in the group with a persistent IgG response (39.6%) and ≤ 7 days in the group with a nonpersistent IgG response (50.0%). The length of hospital stay and supplemental oxygen use were higher in individuals with a persistent IgG response. CONCLUSIONS: The results of the present study show a high frequency of loss of anti-SARS-CoV-2 IgG antibodies within 3 months after COVID-19 diagnosis in the Brazilian Amazon.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abdominal pain and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and lung assessment: 1
    • abdominal pain and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abdominal pain diarrhea and acute phase: 1, 2, 3
    • abdominal pain diarrhea and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain diarrhea and lymphocyte count: 1, 2, 3
    • abdominal pain diarrhea vomiting and acute phase: 1, 2
    • abdominal pain diarrhea vomiting and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain diarrhea vomiting and lymphocyte count: 1
    • abdominal pain diarrhea vomiting nausea and acute phase: 1, 2
    • abdominal pain diarrhea vomiting nausea and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain diarrhea vomiting nausea and lymphocyte count: 1
    • abdominal pain diarrhea vomiting nausea fatigue and acute respiratory syndrome coronavirus: 1, 2
    • acute phase and long duration: 1, 2, 3, 4, 5, 6
    • acute phase and lung assessment: 1, 2
    • acute phase and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome coronavirus and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome coronavirus and low persistence: 1, 2, 3, 4